Big Picture Bio: Revolutionizing Cancer Treatment with AI-Designed Drug Combinations

Big Picture Bio, a BioTech startup based in London, has recently come out of stealth mode with a total funding round of €2.55 million (£2.2 million). This funding includes a €1.75 million (£1.5 million) pre-Seed round co-led by Kadmos Capital and Exceptional Ventures, along with €815k (£700k) in non-dilutive support from Innovate UK’s Investor Partnerships Programme. Gloucester Ventures and angel investor John White also participated in the pre-Seed round.

Remy Kesrouani, Managing Partner at Kadmos Capital, expressed his confidence in the founders, Dr. Kerstin Papenfuss and Dr. Mark Hammond, highlighting their determination and resolve in building successful businesses. He praised Big Picture Bio for its innovative approach to AI in solving complex problems in drug development, particularly in predicting the behavior of clinical trials.

Big Picture Bio’s CEO, Dr. Kerstin Papenfuss, and CTO, Dr. Mark Hammond, have developed a unique “world model” that simulates the interactions between tumors, immune cells, and surrounding tissue. Their goal is to identify the most effective drug combinations and sequences to combat cancer resistance.

Both founders have a strong background in the industry, with experience at Deep Science Ventures. Papenfuss led the therapeutics team at DSV, while Hammond played a key role in the company’s growth. Together, they have worked on various projects focusing on complex diseases.

The company’s predictive approach has already shown promising results, accurately forecasting outcomes in clinical trials and making successful predictions in the field of oncology.

Dr. Kerstin Papenfuss emphasized the importance of developing drug combinations to combat cancer effectively. With over 900 billion possible combinations, their computational models offer a more efficient way to identify suitable treatments.

Big Picture Bio’s advisory team includes experts from the pharmaceutical industry, bringing valuable insights to the table. The company plans to use the funding to accelerate its research and bring AI-designed cancer therapies from computer models to the laboratory.

In conclusion, Big Picture Bio aims to revolutionize the way drug combinations are developed, moving beyond trial-and-error testing. Their innovative approach could pave the way for designing new treatments tailored to individual patients. With a strong team and solid funding, the future looks bright for this London-based BioTech startup.